Item 2.02 Results of Operations and Financial Condition.

On November 9, 2022, Clearside Biomedical, Inc. (the "Registrant") issued a press release announcing its financial results for the quarter ended September 30, 2022, as well as information regarding a conference call to discuss these financial results and the Registrant's recent corporate highlights and the results from the Company's OASIS trial (as discussed below). A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

Also on November 9, 2022, the Registrant issued a press release entitled "Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD." The Company will be discussing the results of the OASIS trial during the conference call noted above. During the conference call, the Company will also be presenting a presentation covering the results of the OASIS trial, which will also be made available on the Registrant's website. A copy of the press release and presentation are furnished herewith as Exhibits 99.2 and 99.3, respectively, to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.2 and 99.3, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits




Exhibit
Number    Exhibit Description
99.1        Press Release, dated November 9, 2022, titled "Clearside Biomedical
          Announces Third Quarter 2022 Financial Results and Provides Corporate
          Update"
99.2        Press release, dated November 9, 2022, titled "Clearside Biomedical
          Announces Positive Results in Safety, Durability and Biologic Effect in
          OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib
          injectable suspension) for the Treatment of Wet AMD"
99.3        Presentation, dated November 9, 2022
104       Cover Page Interactive Data File (embedded with the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses